Biotest Pharmaceuticals Corporation
Biotest Pharmaceuticals Corporation, commonly referred to as Biotest, is a prominent player in the biopharmaceutical industry, headquartered in the United States. Founded in 1946, the company has established itself as a leader in the development and production of high-quality plasma-derived therapies and biotherapeutics, primarily focusing on immunology and haematology. With major operational regions across North America and Europe, Biotest is renowned for its innovative products, including immunoglobulins and clotting factors, which are essential for treating various medical conditions. The company’s commitment to quality and patient care has earned it a strong market position, marked by significant achievements in research and development. Biotest continues to advance the field of biopharmaceuticals, making a meaningful impact on patients' lives worldwide.
DitchCarbon Score
How does Biotest Pharmaceuticals Corporation's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Biotest Pharmaceuticals Corporation's score of 23 is lower than 71% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Biotest Pharmaceuticals Corporation's reported carbon emissions
Biotest Pharmaceuticals Corporation, headquartered in the US, currently does not have specific carbon emissions data available, as indicated by the absence of reported figures. The company is a current subsidiary of Biotest US Corporation, which may influence its climate commitments and emissions reporting. As of now, Biotest Pharmaceuticals Corporation has not established any documented reduction targets or initiatives, nor does it participate in recognised climate pledges such as the Science Based Targets initiative (SBTi). This lack of data and commitments suggests that the company may still be in the early stages of developing a comprehensive climate strategy. In the broader context of the pharmaceutical industry, companies are increasingly recognising the importance of addressing carbon emissions and setting reduction targets. Biotest Pharmaceuticals Corporation will need to align with these industry standards to enhance its sustainability profile and contribute to global climate goals.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Biotest Pharmaceuticals Corporation is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
